Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells

Autor: Sang Hoon Kim, Jae Ho Song, Min Ji Kim, Mun Gu Song, Angel A. Ku, Sourav Bandyopadhyay, Frank McCormick, Sung Eun Kim

Publikováno v: Metabolites, Vol 12, Iss 9, p 831 (2022)

Cancer cells utilize multiple nutrient scavenging mechanisms to support growth and survival in nutrient-poor, hypoxic tumor microenvironments. Among these mechanisms, macropinocytosis has emerged as an important pathway of extracellular nutrient acqu

Externí odkaz: https://doaj.org/article/f7ad4bedccd34f428e9f92309a48d634

Systematic dissection of coding exons at single nucleotide resolution supports an additional role in cell-specific transcriptional regulation.

Autor: Ramon Y Birnbaum, Rupali P Patwardhan, Mee J Kim, Gregory M Findlay, Beth Martin, Jingjing Zhao, Robert J A Bell, Robin P Smith, Angel A Ku, Jay Shendure, Nadav Ahituv

Publikováno v: PLoS Genetics, Vol 10, Iss 10, p e1004592 (2014)

In addition to their protein coding function, exons can also serve as transcriptional enhancers. Mutations in these exonic-enhancers (eExons) could alter both protein function and transcription. However, the functional consequence of eExon mutations

Externí odkaz: https://doaj.org/article/1bc49212af244252823c78c8dcedf49f

Integration of pathway, cellular and genetic context reveals principles of synthetic lethality that affect reproducibility

Autor: Sameera Kongara, Sourav Bandyopadhyay, Di Wu, Angel A. Ku, Xin Zhao, Frank McCormick, Hsien-Ming Hu, Allan Balmain

Synthetic lethal screens have the potential to identify new vulnerabilities incurred by specific cancer mutations but have been hindered by lack of agreement between studies. Using KRAS as a model, we identified that published synthetic lethal screen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38de83fefada43f4323feab7edb23336

Abstract A16: Discovery and functional characterization of essential pathways in KRAS mutant cancers

Autor: Sourav Bandyopadhyay, Angel A. Ku

Publikováno v: Molecular Cancer Therapeutics. 16:A16-A16

KRAS oncogenes are present in 30% of all human cancers and are required for tumor development and maintenance and although clearly important efforts to target KRAS mutant tumors remains a major challenge. Several systematic approaches have been made

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6533b2163723b67da59716cf6d5f7664
https://doi.org/10.1158/1538-8514.synthleth-a16

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Autor: Shah KN; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Bhatt R; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Rotow J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Rohrberg J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Olivas V; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Wang VE; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Hemmati G; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Martins MM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Maynard A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Kuhn J; Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA., Galeas J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Donnella HJ; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Kaushik S; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Ku A; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Dumont S; Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA., Krings G; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Haringsma HJ; Clovis Oncology, Inc., Boulder, CO, USA., Robillard L; Clovis Oncology, Inc., Boulder, CO, USA., Simmons AD; Clovis Oncology, Inc., Boulder, CO, USA., Harding TC; Clovis Oncology, Inc., Boulder, CO, USA., McCormick F; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Goga A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Bivona TG; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Bandyopadhyay S; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA. sourav.bandyopadhyay@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. sourav.bandyopadhyay@ucsf.edu.

Publikováno v: Nature medicine [Nat Med] 2019 Jan; Vol. 25 (1), pp. 111-118. Date of Electronic Publication: 2018 Nov 26.